

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

CLARIFICATION ANNOUNCEMENT
SUPPLEMENTAL NOTICE AND REVISED FORM OF PROXY FOR
THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024

References are made to the annual general meeting of Qyuns Therapeutics Co., Ltd. (the “**Company**”) to be held at North Conference Room, 2nd Floor, Building 1, No.907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, May 31, 2024 at 2:00 p.m. (the “**AGM**”), and the related circular dated April 29, 2024 (the “**Circular**”), the notice of the annual general meeting (the “**Original Notice**”) and the form of proxy (the “**Proxy Form**”) which are published by the Company on April 29, 2024, and the supplemental notice of the AGM (the “**Supplemental Notice**”) and the revised form of proxy (the “**Revised Proxy Form**”) which are published by the Company on May 14, 2024, among which the resolutions to be proposed at the AGM for the approval of the shareholders of the Company (the “**Shareholder(s)**”) were set out.

The Company would like to clarify that resolutions numbered 7 and 9 in respect of the provision of a guarantee by the Company to its subsidiary for a credit line of not more than RMB300 million and the provision of a guarantee by the Company to its subsidiary for a guarantee line of not more than RMB100 million in aggregate, respectively, shall be considered and approved by way of special resolutions.

Save for the above clarification, all information and contents stated in the Circular, the Original Notice, the Supplemental Notice, the Proxy Form and the Revised Proxy Form are correct and remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Circular, the Original Notice, the Supplemental Notice and the Revised Proxy Form.

If a Shareholder has already lodged the Proxy Form or the Revised Proxy Form with the Company or its branch share registrar in Hong Kong, the Proxy Form or the Revised Proxy Form will be treated as the valid form of proxy lodged by such Shareholder if correctly completed. The proxy so appointed pursuant to the Proxy Form or the Revised Proxy Form will also be entitled to vote at his or her discretion on all resolutions duly put to the AGM or any adjourned thereof.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, May 16, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.